Selexipag for the treatment of chronic thromboembolic pulmonary hypertension

202169 citationsJournal Articlehybrid Open Access

Authors

Takeshi Ogo · National Cerebral and Cardiovascular Center

Hiroto Shimokawahara · Okayama Medical Center

Hideyuki Kinoshita · Kyoto University

Seiichiro Sakao · Chiba University

Kohtaro Abe · Kyushu University

Satoaki Matoba · Kyoto Prefectural University of Medicine

Hirohiko Motoki

Abstract

Selexipag significantly improved PVR and other haemodynamic variables in patients with CTEPH, although exercise capacity remained unchanged. Further large-scale investigation is necessary to prove the role of selexipag in CTEPH.

Topics & Keywords

Pulmonary Hypertension Research and Treatments Cardiovascular Issues in Pregnancy Cardiovascular Function and Risk Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Respiratory Journal

Volume 60, Issue 1, pp. 2101694-2101694

DOI: 10.1183/13993003.01694-2021

Field-Weighted Citation Impact: 7.04